Plenary:
Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
◦ Favourable safety profile
◦ Well-tolerated over 24 Wks
◦ Improved ESSDAI, salivary flow, Igs
◦ May be first effective oral disease-modifying therapy for SS
Dorner T Abs1113 t.co/FkgJpwKAJL #ACR22 @RheumNow
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study - ACR Meeting Abstracts
Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
◦ Favourable safety profile
◦ Well-tolerated over 24 Wks
◦ Improved ESSDAI, salivary flow, Igs
◦ May be first effective oral disease-modifying therapy for SS
Dorner T Abs1113 t.co/FkgJpwKAJL #ACR22 @RheumNow
